Halozyme announces notice of allowance for patent claims to second human enzyme.Halozyme Therapeutics, Inc. (San Diego, CA), a biopharmaceutical company developing and commercializing recombinant human enzymes, announced that the United States Patent Trademark Office has given a notice of allowance to both natural and recombinant forms of HTI-101, a second enzyme in Halozyme's pipeline. The patent is licensed exclusively to Halozyme from the University of California, San Francisco . The new patent claims for HTI-101 are directed to a human enzyme normally found in the bloodstream with a mechanism of action that is distinct from Halozyme's FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. approved rHuPH20 enzyme. This new enzyme may prove useful for additional therapeutic applications. Halozyme is currently conducting pre-clinical work with HTI-101 in the fields of oncology and inflammation.
"We are pleased to add these new natural and recombinant composition of matter claims in the '283 patent to Halozyme's growing human enzyme intellectual property estate," said Gregory Frost, PhD, Halozyme's Chief Scientific Officer. "This second enzyme can be readily channeled into our commercially validated molecular engineering systems and mammalian manufacturing processes, and fits nicely with Halozyme's demonstrated ability to develop and commercialize recombinant human enzymes."
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the infertility, palliative care, and oncology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity immunogenicity /im·mu·no·ge·nic·i·ty/ (-je-nis´it-e) the property enabling a substance to provoke an immune response, or the degree to which a substance possesses this property. . The company has received FDA approval for two products: Cumulase, the first and only recombinant human hyaluronidase Hyaluronidase
Any one of a family of enzymes, also known as hyaluronate lyases or spreading factors, produced by mammals, reptiles, insects, and bacteria, which catalyze the breakdown of hyaluronic acid. for cumulus cumulus: see cloud. removal in the IVF IVF in vitro fertilization.
in vitro fertilization
IVF 1 In vitro fertilization, see there 2. Intravascular fluid process; and Hylenex, for use as an adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant)
1. assisting or aiding.
2. a substance that aids another, such as an auxiliary remedy.
3. to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.
Halozyme Therapeutics, Inc.